{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:21:43Z","timestamp":1792012903417,"version":"4.4.0"},"reference-count":32,"publisher":"The Journal of Rheumatology","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To characterize disease-modifying antirheumatic drug (DMARD) use for children with juvenile idiopathic arthritis (JIA) in the United States and to determine patient factors associated with medication use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>We analyzed cross-sectional baseline enrollment data from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry from May 2010 through May 2011 for children with JIA. Current and prior medication use was included. We used parsimonious backward stepwise logistic regression models to calculate OR to estimate associations between clinical patient factors and medication use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>We identified 2748 children with JIA with a median disease duration of 3.9 years from 51 US clinical sites. Overall, 2023 (74%) had ever received a nonbiologic DMARD and 1246 (45%) had ever received a biologic DMARD. Among children without systemic arthritis, methotrexate use was most strongly associated with uveitis (OR 5.2, 95% CI 3.6\u20137.6), anticitrullinated protein antibodies (OR 4.5, 95% CI 1.7\u201312), and extended oligoarthritis (OR 4.1, 95% CI 2.5\u20136.6). Among children without systemic arthritis, biologic DMARD use was most strongly associated with rheumatoid factor (RF)-positive polyarthritis (OR 4.3, 95% CI 2.9\u20136.6), psoriatic arthritis (PsA; OR 3.0, 95% CI 2.0\u20134.4), and uveitis (OR 2.8, 95% CI 2.1\u20133.7). Among children with systemic arthritis, 160 (65%) ever received a biologic DMARD; tumor necrosis factor inhibitor use was associated with polyarthritis (OR 2.5, 95% CI 3.8\u201316), while interleukin 1 inhibitor use was not.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>About three-quarters of all children with JIA in the CARRA Registry received nonbiologic DMARD. Nearly one-half received biologic DMARD, and their use was strongly associated with RF-positive polyarthritis, PsA, uveitis, and systemic arthritis.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.120110","type":"journal-article","created":{"date-parts":[[2012,8,2]],"date-time":"2012-08-02T01:29:34Z","timestamp":1343870974000},"page":"1867-1874","source":"Crossref","is-referenced-by-count":80,"title":["Disease-modifying Antirheumatic Drug Use in the Treatment of Juvenile Idiopathic Arthritis: A Cross-sectional Analysis of the CARRA Registry"],"prefix":"10.3899","volume":"39","author":[{"given":"TIMOTHY","family":"BEUKELMAN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SARAH","family":"RINGOLD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TREVOR E.","family":"DAVIS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ESI MORGAN","family":"DeWITT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CHRISTINA F.","family":"PELAJO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PAMELA F.","family":"WEISS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YUKIKO","family":"KIMURA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2012,8,1]]},"reference":[{"key":"2018112909283402000_39.9.1867.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199204163261602"},{"key":"2018112909283402000_39.9.1867.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200003163421103"},{"key":"2018112909283402000_39.9.1867.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706290"},{"key":"2018112909283402000_39.9.1867.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.22838"},{"key":"2018112909283402000_39.9.1867.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60998-8"},{"key":"2018112909283402000_39.9.1867.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.134254"},{"key":"2018112909283402000_39.9.1867.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60454-7"},{"key":"2018112909283402000_39.9.1867.8","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20460"},{"key":"2018112909283402000_39.9.1867.9","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2018112909283402000_39.9.1867.10","doi-asserted-by":"crossref","unstructured":"Hosmer DW Lemeshow S . Assessing the fit of the model. In: Applied logistic regression. 2nd ed. New York: John Wiley & Sons; 2000:143\u2013202.","DOI":"10.1002\/0471722146.ch5"},{"key":"2018112909283402000_39.9.1867.11","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.041137"},{"key":"2018112909283402000_39.9.1867.12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq308"},{"key":"2018112909283402000_39.9.1867.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.087411"},{"key":"2018112909283402000_39.9.1867.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.087130"},{"key":"2018112909283402000_39.9.1867.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.3.245"},{"key":"2018112909283402000_39.9.1867.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.20793"},{"key":"2018112909283402000_39.9.1867.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.100354"},{"key":"2018112909283402000_39.9.1867.18","first-page":"1146","article-title":"Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: Results of a multinational survey","volume":"34","author":"Foeldvari","year":"2007","journal-title":"J Rheumatol"},{"key":"2018112909283402000_39.9.1867.19","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.103721"},{"key":"2018112909283402000_39.9.1867.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.058248"},{"key":"2018112909283402000_39.9.1867.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.20288"},{"key":"2018112909283402000_39.9.1867.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.23144"},{"key":"2018112909283402000_39.9.1867.23","first-page":"1918","article-title":"Variation in the initial treatment of knee monoarthritis in juvenile idiopathic arthritis: A survey of pediatric rheumatologists in the United States and Canada","volume":"34","author":"Beukelman","year":"2007","journal-title":"J Rheumatol"},{"key":"2018112909283402000_39.9.1867.24","unstructured":"Wallace CA Giannini EH Spalding SJ Hashkes PJ O\u2019Neil KM Zeft AS Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2011 Dec 19 [E-pub ahead of print]."},{"key":"2018112909283402000_39.9.1867.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041810"},{"key":"2018112909283402000_39.9.1867.26","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20521"},{"key":"2018112909283402000_39.9.1867.27","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem053"},{"key":"2018112909283402000_39.9.1867.28","first-page":"1139","article-title":"Prevalence and outcome of juvenile idiopathic arthritis-associated uveitis and relation to articular disease","volume":"34","author":"Grassi","year":"2007","journal-title":"J Rheumatol"},{"key":"2018112909283402000_39.9.1867.29","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-2126-1"},{"key":"2018112909283402000_39.9.1867.30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep352"},{"key":"2018112909283402000_39.9.1867.31","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20044"},{"key":"2018112909283402000_39.9.1867.32","first-page":"234","article-title":"Juvenile idiopathic arthritis classification criteria: Loopholes and diagnosis software","volume":"34","author":"Behrens","year":"2007","journal-title":"J Rheumatol"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.120110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T13:17:55Z","timestamp":1543497475000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.120110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,1]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2012,9,1]]},"published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.3899\/jrheum.120110"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.120110","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,1]]}}}